{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:14:40Z","timestamp":1791609280130,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejca.2019.04.032","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:18:05Z","timestamp":1559391485000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Human papillomavirus vaccination: The ESGO\u2013EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy"],"prefix":"10.1016","volume":"116","author":[{"given":"Elmar A.","family":"Joura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-0735","authenticated-orcid":false,"given":"Maria","family":"Kyrgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco X.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Kesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Niemenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles WE.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Gultekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.04.032_bib1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmi.2015.05.001","article-title":"From the monovalent to the nine-valent HPV vaccine","volume":"21","author":"Pils","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ejca.2019.04.032_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.04.032_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"Hartwig","year":"2015","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.ejca.2019.04.032_bib4","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejca.2019.04.032_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/AOG.0000000000002736","article-title":"Human papillomavirus genotypes from vaginal and vulvar intraepithelial neoplasia in females 15-26 Years of age","volume":"132","author":"Garland","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2019.04.032_bib6","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.04.032_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2019.04.032_bib8","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2019.04.032_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 Years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.04.032_bib11","doi-asserted-by":"crossref","first-page":"djt460","DOI":"10.1093\/jnci\/djt460","article-title":"Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2019.04.032_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in england using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016","volume":"218","author":"Mesher","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib13","doi-asserted-by":"crossref","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2019.04.032_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib16","doi-asserted-by":"crossref","first-page":"i3633","DOI":"10.1136\/bmj.i3633","article-title":"Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis","volume":"354","author":"Kyrgiou","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2019.04.032_bib17","doi-asserted-by":"crossref","first-page":"g6192","DOI":"10.1136\/bmj.g6192","article-title":"Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis","volume":"349","author":"Kyrgiou","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2019.04.032_bib18","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2019.04.032_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.amepre.2018.03.013","article-title":"Cervical cancer incidence in young U.S. Females after human papillomavirus vaccine introduction","volume":"55","author":"Guo","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ejca.2019.04.032_bib20","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ejca.2019.04.032_bib21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejca.2019.04.032_bib22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-Valent HPV vaccine: a combined analysis of 7 Phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejca.2019.04.032_bib23","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ejca.2019.04.032_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/jir281","article-title":"Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses","volume":"204","author":"Westra","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-151-8-200910200-00007","article-title":"Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States","volume":"151","author":"Kim","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2019.04.032_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","article-title":"Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies","volume":"18","author":"Lehtinen","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ejca.2019.04.032_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jiv368","article-title":"Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs","volume":"213","author":"Elfstr\u00f6m","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12962-017-0080-9","article-title":"Cost-effectiveness of human papillomavirus vaccination in Germany","volume":"15","author":"Damm","year":"2017","journal-title":"Cost Eff Resour Allocation"},{"key":"10.1016\/j.ejca.2019.04.032_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.ejca.2019.04.032_bib30","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2019.04.032_bib31","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2019.04.032_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2019.04.032_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2019.04.032_bib34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2016.71.4543","article-title":"Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study","volume":"35","author":"Ebisch","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.04.032_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ypmed.2018.12.014","article-title":"Mode of HPVvaccination delivery and equity in vaccine uptake: a nationwide cohort study","volume":"120","author":"Wang","year":"2019","journal-title":"Prev Med"},{"key":"10.1016\/j.ejca.2019.04.032_bib36","unstructured":"https:\/\/www.who.int\/immunization\/diseases\/hpv\/en\/."},{"key":"10.1016\/j.ejca.2019.04.032_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejca.2019.04.032_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.vaccine.2015.12.063","article-title":"Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ejca.2019.04.032_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"Bosch","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T04:11:24Z","timestamp":1561695084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"alternative-id":["S0959804919302886"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.04.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccination: The ESGO\u2013EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}